Search Result

Results for "

antiepileptic effect

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ATP Synthase (1) Calcium Channel (1) DNA Methyltransferase (4) Drug Derivative (3) Drug Metabolite (1) Endogenous Metabolite (1) FAAH (1) Fungal (1) GABA Receptor (1) GlyT (1) Isotope-Labeled Compounds (2) LPL Receptor (1) MAGL (2) Organoid (2) Reference Standards (4) ROCK (3) Sodium Channel (4) Tau Protein (2)
By Research Areas:	Cancer (7) Cardiovascular Disease (1) Inflammation/Immunology (1) Neurological Disease (21)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10583

Y-27632 dihydrochloride Maximum Cited Publications 532 Publications Verification	Organoid ROCK	Neurological Disease Cancer
Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor (ROCK-I K_i=220 nM; ROCK-II K_i=300 nM). Y-27632 dihydrochloride shows antiepileptic effects .

HY-B0106

Levetiracetam 2 Publications Verification UCB L059	DNA Methyltransferase	Neurological Disease Cancer
Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .

HY-10583G

Y-27632 dihydrochloride 1 Publications Verification	ROCK	Neurological Disease Cancer
Y-27632 dihydrochloride (GMP) is the GMP level of Y-27632 dihydrochloride (HY-10583). GMP guidelines are used to produce Y-27632 dihydrochloride (GMP). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor with antiepileptic effect .

HY-10583R

Y-27632 dihydrochloride (Standard) Maximum Cited Publications 532 Publications Verification	ROCK Organoid Reference Standards	Cancer
Y-27632 dihydrochloride (Standard) is the analytical standard of Y-27632 dihydrochloride. Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor (ROCK-I K_i=220 nM; ROCK-II K_i=300 nM). Y-27632 dihydrochloride shows antiepileptic effects .

HY-177093

Irafamdastat BMS-986368; CC-97489; ABX-1772	MAGL FAAH	Neurological Disease
Irafamdastat (BMS-986368) (Example 74) is a FAAH and MAGL inhibitor, with IC₅₀s ≤ 100 nM (human FAAH) and 100 nM-1 μM (human MAGL) respectively. Irafamdastat has antiepileptic effect .

HY-14948

Carisbamate 1 Publications Verification RWJ-333369	Sodium Channel	Neurological Disease
Carisbamate (RWJ-333369) is an orally active neuromodulator. Carisbamate prevents the development and production of epilep-like discharges and has a neuroprotective effect after in vitro epilepticus-like injury. Carisbamate has good antiepileptic activity in genetic models of generalized and nonconvulsive epilepsy .

HY-B0106R

Levetiracetam (Standard) UCB L059 (Standard)	Reference Standards DNA Methyltransferase	Neurological Disease Cancer
Levetiracetam (Standard) is the analytical standard of Levetiracetam. This product is intended for research and analytical applications. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .

HY-164964

TRV045	LPL Receptor	Neurological Disease
TRV045 is a selective Sphingosine-1-phosphate subtype 1 receptor agonist with no effect on lymphocyte transport. TRV045 has antiepileptic activity .

HY-105022

Sabeluzole R 58735	Tau Protein	Neurological Disease
Sabeluzole (R 58735), a benzothiazol derivative, has antiischemic, antiepileptic, and cognitive-enhancing properties. Sabeluzole protects rat hippocampal neurons against NMDA- and glutamate-induced neurotoxicity via preventing tau expression. Sabeluzole enhances memory in rats, and prevents the amnesic effect of Chlordiazepoxide. Sabeluzole can be used fro research of Alzheimer's disease .

HY-B0106S

Levetiracetam-d6 UCB L059-d₆	Isotope-Labeled Compounds DNA Methyltransferase	Neurological Disease Cancer
Levetiracetam-d₆ is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .

HY-118931

EF-1502	GABA Receptor	Neurological Disease
EF-1502 is a potent and selective GABA transporter inhibitor with GAT1 and BGT1 inhibitory activity. EF-1502 produces a synergistic anti-epileptic effect when used in combination with Tiagabine (HY-B0696), a compound used to suppress epileptic seizures. The dosing combination of EF-1502 exhibited reduced anti-epileptic efficacy and dyskinesia when used with THIP (HY-10232). The mechanism of EF-1502 differs significantly from Tiagabine, suggesting a unique role in the inhibitory strategy .

HY-176065

Nav1.2-IN-1	Sodium Channel	Neurological Disease
Nav1.2-IN-1 (compound 5i), a 3-(1,2,3,6-tetrahydropyridine)-4-azaindole derivative, is a potent and selective Nav1.2 inhibitor. Nav1.2-IN-1 induces a reduction in the peak amplitude of Nav1.2 currents with an IC₅₀ value of 7.79 μM. Nav1.2-IN-1 exhibits antiepileptic activity. Nav1.2-IN-1 shows high anticonvulsant effect and low neurotoxicity in subcutaneous Pentetrazole (sc-PTZ)-induced epilepsy mode .

HY-W016509

epi-Inositol	Drug Derivative	Neurological Disease
epi-Inositol, a inositol analog, is an antidepressant agent. epi-Inositol shows regulatory effects on expression of the most highly regulated gene in the inositol biosynthetic pathway. epi-Inositol shows antiepileptic effect .

HY-132246

WWL123 analogue-1	MAGL	Neurological Disease
WWL123 analogue-1 is an analogue of WWL123. WWL123 is a potent and selective ABHD6 inhibitor with an IC₅₀ of 430 nM . WWL123 crosses the blood-brain-barrier and inhibits ABHD6 in brain parenchyma. ABHD6 blockade by WWL123 exerts an antiepileptic effect in Pentylenetetrazole (PTZ)-induced epileptiform seizures and spontaneous seizures in R6/2 mice .

HY-111189

GSK931145	GlyT	Neurological Disease
GSK931145 is a glycine transporter 1 (GlyT1) inhibitor with anti-epileptic activity. GSK931145 exhibits a low minimum effective dose in the maximum electrical stimulation threshold test, indicating that it has a significant anti-epileptic effect. GSK931145 is also suitable as a positron emission tomography (PET) radioligand for quantifying the availability of glycine transporters in the living brain .

HY-12155

JNJ-26990990	Sodium Channel Calcium Channel	Neurological Disease
JNJ-26990990 is a broad-spectrum antiepileptic agent with oral activity. JNJ-26990990 can inhibit voltage-gated Na ⁺ channels and N-type Ca ²⁺ channels, but has a very weak inhibitory effect on human carbonic anhydrase-II (IC₅₀ = 110 μM) .

HY-B0106S1

Levetiracetam-d3 UCB L059-d₃	DNA Methyltransferase	Neurological Disease Cancer
Levetiracetam-d₃ is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .

HY-12772R

Hydroxy Itraconazole (Standard) Itraconazole metabolite Hydroxy Itraconazole (Standard); R-63373 (Standard)	Reference Standards Fungal Drug Metabolite	Others
Levetiracetam (Standard) is the analytical standard of Levetiracetam. This product is intended for research and analytical applications. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .

HY-W016509R

epi-Inositol (Standard)	Endogenous Metabolite Drug Derivative	Neurological Disease
epi-Inositol (Standard) is the analytical standard of epi-Inositol (HY-W016509). This product is intended for research and analytical applications. epi-Inositol, a inositol analog, is an antidepressant agent. epi-Inositol shows regulatory effects on expression of the most highly regulated gene in the inositol biosynthetic pathway. epi-Inositol shows antiepileptic effect .

HY-105022R

Sabeluzole (Standard) R 58735 (Standard)	Reference Standards Tau Protein	Neurological Disease
Sabeluzole (Standard) is the analytical standard of Sabeluzole. This product is intended for research and analytical applications. Sabeluzole (R 58735), a benzothiazol derivative, has antiischemic, antiepileptic, and cognitive-enhancing properties. Sabeluzole protects rat hippocampal neurons against NMDA- and glutamate-induced neurotoxicity via preventing tau expression. Sabeluzole enhances memory in rats, and prevents the amnesic effect of Chlordiazepoxide. Sabeluzole can be used fro research of Alzheimer's disease .

HY-W707539

Carisbamate-d2,-15N RWJ-333369-d_215N	Isotope-Labeled Compounds Sodium Channel	Neurological Disease
Carisbamate-d₂,- ¹⁵N (RWJ-333369-d₂,- ¹⁵N) is the deuterium labeled Carisbamate (HY-14948). Carisbamate (RWJ-333369) is an orally active neuromodulator. Carisbamate prevents the development and production of epilep-like discharges and has a neuroprotective effect after in vitro epilepticus-like injury. Carisbamate has good antiepileptic activity in genetic models of generalized and nonconvulsive epilepsy .

HY-116685

AF-CX 1325	Others	Neurological Disease
AF-CX 1325 has strongest antiepileptic effect .

HY-148605

Aloracetam	ATP Synthase Drug Derivative	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Aloracetam is a γ-aminobutyric acid cyclic derivative that can pass through the blood-brain barrier and has a significant enhancing cognitive function effect. Aloracetam improves the blood perfusion of brain tissue, increases the synthesis of proteins, ATP and acetylcholine in the brain, enhances the excitatory conduction effect of cholinergic nerves, and reduces the damage to brain tissue caused by cerebral vascular diseases. Aloracetam also has certain anti-epileptic, anti-inflammatory, analgesic and anti-depressant effects .

Cat. No.	Product Name	Type

HY-10583G

Y-27632 dihydrochloride 1 Publications Verification	Fluorescent Dyes
Y-27632 dihydrochloride (GMP) is the GMP level of Y-27632 dihydrochloride (HY-10583). GMP guidelines are used to produce Y-27632 dihydrochloride (GMP). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor with antiepileptic effect .

Cat. No.	Product Name	Type

HY-10583G

Y-27632 dihydrochloride 1 Publications Verification	Biochemical Assay Reagents
Y-27632 dihydrochloride (GMP) is the GMP level of Y-27632 dihydrochloride (HY-10583). GMP guidelines are used to produce Y-27632 dihydrochloride (GMP). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor with antiepileptic effect .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W016509

epi-Inositol	Natural Products Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Drug Derivative
epi-Inositol, a inositol analog, is an antidepressant agent. epi-Inositol shows regulatory effects on expression of the most highly regulated gene in the inositol biosynthetic pathway. epi-Inositol shows antiepileptic effect .

HY-W016509R

epi-Inositol (Standard)	Natural Products Endogenous metabolite Source Classification	Endogenous Metabolite Drug Derivative
epi-Inositol (Standard) is the analytical standard of epi-Inositol (HY-W016509). This product is intended for research and analytical applications. epi-Inositol, a inositol analog, is an antidepressant agent. epi-Inositol shows regulatory effects on expression of the most highly regulated gene in the inositol biosynthetic pathway. epi-Inositol shows antiepileptic effect .

Cat. No.	Product Name	Chemical Structure

HY-B0106S

Levetiracetam-d6
Levetiracetam-d₆ is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .

HY-B0106S1

Levetiracetam-d3
Levetiracetam-d₃ is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent .

HY-W707539

Carisbamate-d2,-15N
Carisbamate-d₂,- ¹⁵N (RWJ-333369-d₂,- ¹⁵N) is the deuterium labeled Carisbamate (HY-14948). Carisbamate (RWJ-333369) is an orally active neuromodulator. Carisbamate prevents the development and production of epilep-like discharges and has a neuroprotective effect after in vitro epilepticus-like injury. Carisbamate has good antiepileptic activity in genetic models of generalized and nonconvulsive epilepsy .

Carisbamate-d2,-15N

Carisbamate-d₂,- ¹⁵N (RWJ-333369-d₂,- ¹⁵N) is the deuterium labeled Carisbamate (HY-14948). Carisbamate (RWJ-333369) is an orally active neuromodulator. Carisbamate prevents the development and production of epilep-like discharges and has a neuroprotective effect after in vitro epilepticus-like injury. Carisbamate has good antiepileptic activity in genetic models of generalized and nonconvulsive epilepsy .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10583G

Y-27632 dihydrochloride 1 Publications Verification	ROCK	Neurological Disease Cancer
Y-27632 dihydrochloride (GMP) is the GMP level of Y-27632 dihydrochloride (HY-10583). GMP guidelines are used to produce Y-27632 dihydrochloride (GMP). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor with antiepileptic effect .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

antiepileptic effect

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

GMP Molecules

Natural
Products